Sponsor: Kartos Therapeutics
Sponsor Study ID: KRT-232-115
Study Title: KRT-232-115: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Versus Placebo Plus Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post PV MF), or Post Essential Thrombocythemia (post ET MF) That Have a Suboptimal Response to Ruxolitinib
CTO #: 104063
NCT Number: NCT06479135
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Other Hematopoietic
Study Objectives: To compare SVR35 between Arm 1 and Arm 2. To compare TSS50 between Arm 1 and Arm 2. To compare SVR25 between Arm 1 and Arm 2. To compare TSS30 between Arm 1 and Arm 2.